Takami, Christine
Savinen, Suvi
Sjölander, Arvid
Chang, Zheng
Brikell, Isabell
Kuja-Halkola, Ralf
D’Onofrio, Brian M.
Gudbjornsdottir, Soffia
Garcia-Argibay, Miguel
Larsson, Henrik
Pettersson, Erik
Lichtenstein, Paul
Landén, Mikael
Funding for this research was provided by:
Karolinska Institutet
Stiftelsen Professor Bror Gadelius Minnesfond
Takeda Pharmaceuticals
Vetenskapsrådet
Hjärnfonden/the Swedish Brain foundation
Vinnova
Article History
Received: 6 November 2025
Accepted: 24 April 2026
First Online: 8 May 2026
Change Date: 21 June 2026
Change Type: Update
Change Details: The original online version of this article was revised: Figure 2 is currently incorrect as it is a duplication of Figure 1 and it has updated.
Change Date: 30 June 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s40345-026-00432-y
Declarations
:
: This study was approved by the Swedish Ethical Review Authority (registration number 2020–06540). Informed consent was waived, as all data were anonymized by Statistics Sweden immediately after linkage. To protect participant confidentiality, results for outcomes affecting fewer than five individuals are not reported.
: Not applicable.
: HL reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB; all outside the submitted work. HL is editor-in-chief of JCPP Advances. ML has received lecture honoraria from Lundbeck pharmaceuticals, outside the submitted work.